A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy
Latest Information Update: 09 Nov 2025
At a glance
- Drugs Calcium/magnesium/potassium/sodium oxybate (Primary)
- Indications Idiopathic hypersomnia; Narcolepsy
- Focus Therapeutic Use
- Acronyms DUET
- Sponsors Jazz Pharmaceuticals plc
Most Recent Events
- 22 Sep 2025 Results presented at Jazz Pharmaceuticals plc media release
- 22 Sep 2025 According to Jazz Pharmaceuticals plc media release, new results from this trial were presented at World Sleep 2025, held in Singapore from September 5-10, 2025, as well as the 38th annual Psych Congress, held in San Diego from September 17-21, 2025.
- 09 Jun 2025 According to Jazz Pharmaceuticals plc media release, data from this trial presented at the SLEEP 2025